Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(1), P. 121 - 121

Published: Jan. 16, 2025

In the 21st century, thanks to advances in biotechnology and developing pharmaceutical technology, significant progress is being made effective drug design. Drug targeting aims ensure that acts only pathological area; it defined as ability accumulate selectively quantitatively target tissue or organ, regardless of chemical structure active substance method administration. With targeting, conventional, biotechnological gene-derived drugs body’s organs, tissues, cells can be transported specific regions. These systems serve carriers regulate timing release. Despite having many advantageous features, these have limitations thoroughly treating complex diseases such cancer. Therefore, combining with nanoparticle technologies imperative treat cancer at both local systemic levels effectively. The nanocarrier-based delivery involves encapsulating target-specific molecules into polymeric vesicular systems. Various (DDS) were investigated discussed this review article. first part passive systems, hydrogels, thermoplastics, microdevices transdermal-based second carrier nanobiotechnology (carbon nanotubes, nanoparticles, coated, pegylated, solid lipid nanoparticles smart nanogels). third part, advantages discussed, finally, market research commercial used nanotechnological approaches was included.

Language: Английский

---

Therapeutic strategy of biological macromolecules based natural bioactive compounds of diabetes mellitus and future perspectives: A systematic review

Heliyon, Journal Year: 2024, Volume and Issue: 10(2), P. e24207 - e24207

Published: Jan. 1, 2024

High blood glucose levels are a hallmark of the metabolic syndrome known as diabetes mellitus. More than 600 million people will have by 2045 global prevalence disease continues to rise. Contemporary antidiabetic drugs reduce hyperglycemia and its consequences. However, these come with undesirable side effects, so it's encouraging that research into plant extracts bioactive substances characteristics is on Natural remedies preferable conventional anti-diabetic since they safer for body, more affordable fewer potential adverse effects. Biological macromolecules such liposomes, niosomes, polymeric nanoparticles, solid lipid nanoemulsions metallic nanoparticles explored in this review. Current drug restrictions been addressed, effectiveness plant-based therapies has enhanced merits methods. Plant extracts' loading capacity carriers' stability primary obstacles developing nanocarriers. Hydrophilic, hydrophobic, amphiphilic covered, brief overview amphipathic features phospholipids, nanocarriers provided. Metallic nanoparticles' benefits attendant risks highlighted emphasize their efficiency treating hyperglycemia. Researchers interested loaded therapeutics may find current helpful

Language: Английский

---

The Advancement and Obstacles in Improving the Stability of Nanocarriers for Precision Drug Delivery in the Field of Nanomedicine

Current Topics in Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 24(8), P. 686 - 721

Published: Feb. 27, 2024

Nanocarriers have emerged as a promising class of nanoscale materials in the fields drug delivery and biomedical applications. Their unique properties, such high surface area- tovolume ratios enhanced permeability retention effects, enable targeted therapeutic agents to specific tissues or cells. However, inherent instability nanocarriers poses significant challenges their successful application. This review highlights importance nanocarrier stability applications its impact on biocompatibility, delivery, long shelf life, performance, efficacy, reduced side prolonged circulation time, delivery. Enhancing requires careful design, engineering, optimization physical chemical parameters. Various strategies cutting-edge techniques employed improve are explored, with focus By understanding advances stability, this aims contribute development implementation nanocarrier- based therapies clinical settings, advancing field nanomedicine.

Language: Английский

---

Lipid and Transcriptional Regulation in a Parkinson's Disease Mouse Model by Intranasal Vesicular and Hexosomal Plasmalogen‐Based Nanomedicines

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(14)

Published: Feb. 22, 2024

Plasmalogens (vinyl-ether phospholipids) are an emergent class of lipid drugs against various diseases involving neuro-inflammation, oxidative stress, mitochondrial dysfunction, and altered metabolism. They can activate neurotrophic neuroprotective signaling pathways but low bioavailabilities limit their efficiency in curing neurodegeneration. Here, liquid crystalline nanoparticles (LNPs) created for the protection non-invasive intranasal delivery purified scallop-derived plasmalogens. The vivo results with a transgenic mouse Parkinson's disease (PD) model (characterized by motor impairments α-synuclein deposition) demonstrate crucial importance LNP composition, which determines self-assembled nanostructure type. Vesicle hexosome nanostructures small-angle X-ray scattering) display different efficacy nanomedicine-mediated recovery function, balance, transcriptional regulation (e.g., reduced neuro-inflammation PD pathogenic gene expression). Intranasal vesicular hexosomal plasmalogen-based treatment leads to improvement behavioral symptoms downregulation Il6, Il33, Tnfa genes. Moreover, RNA-sequencing lipidomic analyses establish dramatic effect nanomedicines on amelioration, metabolism, type number responsive transcripts that may be implicated neuroregeneration.

Language: Английский

---

MicroRNAs in Parkinson’s disease: From pathogenesis to diagnostics and therapeutic strategies

Neuroscience, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Nanomedicine: a cost-effective and powerful platform for managing neurodegenerative diseases

Metabolic Brain Disease, Journal Year: 2025, Volume and Issue: 40(3)

Published: March 11, 2025

Language: Английский

---

CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson’s Disease

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(6), P. 1252 - 1252

Published: June 13, 2022

Parkinson’s disease (PD) and other chronic debilitating neurodegenerative diseases (NDs) impose a substantial medical, emotional, financial burden on individuals society. The origin of PD is unknown due to complex combination hereditary environmental risk factors. However, over the last several decades, significant amount available data from clinical experimental studies has implicated neuroinflammation, oxidative stress, dysregulated protein degradation, mitochondrial dysfunction as primary causes neurodegeneration. new gene-editing techniques hold great promise for research therapy NDs, such PD, which there are currently no effective disease-modifying treatments. As result, gene may offer treatment options, transforming our ability treat this disease. We present detailed overview novel delivery vehicles, essential their successful implementation in both cutting-edge prospective therapeutics. Moreover, we review most recent advancements CRISPR-based applications therapies better understanding treating PD. explore benefits drawbacks using them range brain, emphasizing some fascinating possibilities.

Language: Английский

---

Advancements in the Application of Nanomedicine in Alzheimer’s Disease: A Therapeutic Perspective

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(18), P. 14044 - 14044

Published: Sept. 13, 2023

Alzheimer’s disease (AD) is a progressive neurodegenerative that affects most people worldwide. AD complex central nervous system disorder. Several drugs have been designed to cure AD, but with low success rates. Because the blood–brain and blood–cerebrospinal fluid barriers are two protect system, their presence has severely restricted efficacy of many treatments studied for diagnosis and/or therapy. The use nanoparticles treatment focus an established rapidly developing field nanomedicine. Recent developments in nanomedicine made it possible effectively transport brain. However, numerous obstacles remain successful nanomedicines clinical settings treatment. Furthermore, given rapid advancement therapeutics, better outcomes patients can be anticipated. This article provides overview recent using different types management AD.

Language: Английский

---

Advancing the understanding of diabetic encephalopathy through unravelling pathogenesis and exploring future treatment perspectives

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 100, P. 102450 - 102450

Published: Aug. 10, 2024

Language: Английский

---

A Comprehensive Review of Cross-Linked Gels as Vehicles for Drug Delivery to Treat Central Nervous System Disorders

Gels, Journal Year: 2022, Volume and Issue: 8(9), P. 563 - 563

Published: Sept. 6, 2022

Gels are attractive candidates for drug delivery because they easily producible while offering sustained and/or controlled release through various mechanisms by releasing the therapeutic agent at site of action or absorption. can be classified based on characteristics including nature solvents used during preparation and method cross-linking. The development novel gel systems local systemic in a sustained, controlled, targetable manner has been epitome recent advances systems. Cross-linked gels modified altering their polymer composition content pharmaceutical biomedical applications. These modifications have resulted stimuli-responsive functionalized dosage forms that offer many advantages effective dosing drugs Central Nervous System (CNS) conditions. In this review, literature concerning cross-linked to CNS explored. Injectable non-injectable formulations intended treatment diseases together with impact studies involving discussed.

Language: Английский

---